Integrated Analysis of Single-Cell and Transcriptome Data Reveals Temporal Dynamics of Microglial Phagocytic Reprogramming in Neuropathic Pain Progression

Technical Summary: Integrated Analysis of Single-Cell and Transcriptome Data Reveals Temporal Dynamics of Microglial Phagocytic Reprogramming in Neuropathic Pain Progression

Problem Statement
Neuropathic pain (NP) is a debilitating chronic condition characterized by maladaptive neuroplasticity that persists beyond tissue healing. While microglia in the spinal dorsal horn are recognized as central regulators of neuroimmune crosstalk and pain sensitization, the specific temporal evolution of their functional states—particularly regarding phagocytic reprogramming—during the transition from acute to chronic pain remains poorly defined. A critical gap exists in understanding how microglial phagocytic functions (such as the clearance of apoptotic cells) evolve over time and whether dysregulation in these processes contributes to the chronification of pain.

Methodology
The study employed a multi-omics approach integrating bioinformatic analysis with in vivo and in vitro experimental validation:

1. Bioinformatic Integration: The authors analyzed five publicly available datasets from the Gene Expression Omnibus (GEO). This included two bulk RNA-seq datasets (GSE111216, GSE241361) and three single-cell RNA-seq (scRNA-seq) datasets (GSE134003, GSE246288, GSE162807) derived from mouse spinal cords following spared nerve injury (SNI).

   • Bulk Analysis: Differential expression analysis (DESeq2), Gene Ontology (GO), KEGG pathway enrichment, and Gene Set Enrichment Analysis (GSEA) were performed to identify inflammation and phagocytosis signatures.
   • Single-Cell Analysis: Using Seurat, Harmony, and Monocle, the authors performed quality control, batch correction, clustering, and pseudotime trajectory analysis. They utilized Gene Set Variation Analysis (GSVA) and CellChat to assess pathway activity and intercellular communication.
   • Gene Screening: A specific filtering strategy identified genes persistently upregulated across post-injury time points (days 3, 7, and 14) within phagocytic microglial clusters, focusing on those annotated with phagocytosis-related GO terms.

2. Experimental Validation:

   • Animal Model: Male and female C57BL/6J mice underwent SNI or sham surgery. Behavioral assessments (mechanical allodynia via von Frey filaments; cold hyperalgesia) were conducted at days 3, 7, and 14.
   • Intervention: Intrathecal injection of the Axl inhibitor R428 (Bemcentinib) was administered to naive mice to assess the role of Axl in pain sensitivity.
   • Molecular & Cellular Assays:
     • In vivo: Immunofluorescence (Iba-1, c-Fos, Axl, cleaved Caspase-3) and Western Blotting (cytokines, p-p38, p-ERK, p-JNK) were performed on spinal cord tissues at day 14.
     • In vitro: BV2 microglial cells were treated with LPS to induce activation and co-cultured with UV-induced apoptotic primary neurons to assess phagocytic capacity. The effect of R428 on this process was quantified.
   • Gene Expression: RT-qPCR was used to validate the expression of eight candidate phagocytosis-related genes in spinal cord tissue.

Key Contributions and Results

1. Temporal Phases of Microglial Reprogramming:
   The study delineates a tri-phasic temporal evolution of spinal microglia following nerve injury:

   • Acute Phase (Day 3): Characterized by a proliferative state with activation of cell cycle, protein synthesis, and interferon signaling pathways.
   • Transitional Phase (Day 7): Marked by a significant upregulation of phagocytic pathways, specifically FcγR-mediated phagocytosis and efferocytosis.
   • Chronic Phase (Day 14): Defined by a sustained activated state where phagocytic function is maintained through the integration of autophagy pathways, suggesting a compensatory mechanism to sustain clearance.

2. Microglial Heterogeneity and Fate Bifurcation:
   Single-cell analysis revealed distinct microglial subpopulations. Pseudotime trajectory analysis demonstrated that microglia diverge from a common progenitor into two distinct fates:

   • A pro-inflammatory lineage (enriched in TNFα signaling and ribosomal biogenesis).
   • A specialized phagocytic lineage (enriched in lysosomal activity, endocytosis, and efferocytosis).
     Specific clusters (e.g., Micro3/Micro5 for inflammation; Clusters 6/7 for phagocytosis) were identified as functionally distinct.

3. Identification of Axl as a Critical Regulator:
   From a screen of 523 persistently upregulated genes, eight phagocytosis-related candidates were identified, with Axl showing the most significant upregulation in the chronic phase.

   • In vivo: Axl expression was significantly elevated in spinal microglia at day 14 post-SNI. Co-localization studies confirmed increased microglial engulfment of apoptotic cells (cleaved Caspase-3+).
   • Functional Impact: Intrathecal inhibition of Axl in naive mice induced mechanical allodynia, indicating that Axl signaling is necessary for pain homeostasis.
   • In vitro: LPS stimulation induced a biphasic phagocytic response (enhancement at 1–3 hours, decline at 6–12 hours). Inhibition of Axl significantly impaired the phagocytic capacity of activated microglia.

4. Dual-Phase Model of Phagocytosis:
   The authors propose a model where microglial phagocytosis plays a dual, time-dependent role:

   • Early Phase: Enhanced but potentially non-selective phagocytosis may contribute to pain chronification by disrupting the excitation-inhibition balance (e.g., clearing inhibitory synapses).
   • Chronic Phase: Impaired efferocytosis due to a "decoupling" of phagocytosis and lysosomal degradation leads to the accumulation of apoptotic debris, sustaining neuroinflammation. Axl upregulation represents an endogenous compensatory attempt to clear this debris, which is insufficient to fully resolve the pathology.

Significance and Claims
The paper claims to provide the first systematic spatiotemporal map of microglial phagocytic reprogramming in the context of neuropathic pain. Its primary significance lies in:

• Mechanistic Insight: Moving beyond static "M1/M2" classifications to reveal a dynamic, bifurcated differentiation trajectory and a time-dependent functional reprogramming of microglia.
• Therapeutic Target: Identifying Axl as a promising therapeutic target. The study suggests that enhancing Axl-mediated efferocytosis could restore microglial function, clear apoptotic debris, and resolve chronic neuroinflammation, rather than simply suppressing microglial activation.
• Stage-Specific Intervention: The findings support the development of stage-specific therapeutics that account for the shifting roles of microglia from early pain initiation to chronic pain maintenance.

The authors maintain modesty regarding their claims, acknowledging limitations such as the reliance on murine data, the need for further validation of the regulatory networks involving Axl, and the complexity of microglial phagocytosis targets (synapses vs. apoptotic cells). They posit that their work offers a theoretical framework for future stage-specific interventions rather than a definitive clinical solution.